Inhibitory effects of erythromycin on wear debris-induced VEGF/Flt-1 gene production and osteolysis
- First Online:
- Cite this article as:
- Markel, D.C., Zhang, R., Shi, T. et al. Inflamm. Res. (2009) 58: 413. doi:10.1007/s00011-009-0007-9
- 132 Downloads
A highly vascularized and inflammatory periprosthetic tissue augments the progress of aseptic loosening, a major clinical problem after total joint replacement. The purpose of this study is to investigate the effect of erythromycin (EM) on ultra high molecular weight polyethylene (UHMWPE) particle-induced VEGF/VEGF receptor 1 (Flt-1) gene production and inflammatory osteolysis in a mouse model.
UHMWPE particles were introduced into established air pouches on BALB/c mice, followed by implantation of calvaria bone from syngeneic littermates. EM treatment started 2 weeks after bone implantation (5 mg/kg day, i.p. injection). Mice without drug treatment as well as mice injected with saline alone were included. Pouch tissues were harvested 2 weeks after bone implantation. Expression of VEGF, Flt-1, RANKL, IL-1, TNF and CD68 was measured by immunostain and RT-PCR, and implanted bone resorption was analyzed by micro-CT (μCT).
Exposure to UHMWPE induced pouch tissue inflammation, increase of VEGF/Flt-1 proteins, and increased bone resorption. EM treatment significantly improved UHMWPE particle-induced tissue inflammation, reduced VEGF/Flt-1 protein expression, and diminished the number of TRAP+ cells, as well as the implanted bone resorption.
This study demonstrated that EM inhibited VEGF and Flt-1 gene expression. The molecular mechanism of EM action on VEGF/Flt-1 signaling-mediated osteoclastogenesis warrants further investigation.
KeywordsVEGFOsteolysisOsteoclastogenesisErythromycinAnimal modelWear debris
Vascular endothelial growth factor
VEGF receptor I
VEGF receptor II
Receptor activator of NF-κB
Tumor necrosis factor
Tartrate-resistant acid phosphatase